GlassScriptPhysician profile
Charis Whitney
NPI 1568876597
$1,811.18
in general payments reported to CMS, 2019-2025
19 companies · $482 in 2025
The $482 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2022: $185 · 2023: $391 · 2024: $498 · 2025: $482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,287 · Education: $83.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,287.45 |
| Education | $83.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $331.92 | 2023-2025 | Acthar |
| Amgen INC. | $273.22 | 2023-2025 | Krystexxa, Tavneos |
| Opko Pharmaceuticals, LLC | $178.35 | 2022-2025 | Rayaldee |
| Travere Therapeutics, INC. | $150.15 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $147.46 | 2022-2025 | Farxiga, Lokelma |
| Mallinckrodt Enterprises LLC | $112.16 | 2019 | |
| Baxter Healthcare | $93.24 | 2019 | |
| Horizon Therapeutics Plc | $63.81 | 2022-2023 | Krystexxa |
| Lilly USA, LLC | $58.53 | 2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $57.47 | 2022-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $54.00 | 2022-2025 | Tarpeyo |
| Biocompatibles, INC. | $50.00 | 2019 | |
| Glaxosmithkline, LLC. | $47.88 | 2022-2023 | Benlysta |
| Novo Nordisk INC | $44.82 | 2024 | Ozempic, Rybelsus |
| Vifor Pharma, INC. | $42.32 | 2025 | Veltassa |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.29 | 2025 | Jardiance |
| Cormedix INC. | $28.36 | 2024 | Defencath |
| Daiichi Sankyo INC. | $27.87 | 2023-2024 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $19.33 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charis Whitney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.